# Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody

> **NCT03183024** · PHASE4 · COMPLETED · sponsor: **Jonathan A. Bernstein, MD** · enrollment: 12 (actual)

## Conditions studied

- Chronic Idiopathic Urticaria

## Interventions

- **BIOLOGICAL:** benralizumab
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT03183024
- **Lead sponsor:** Jonathan A. Bernstein, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-12
- **Primary completion:** 2018-11-06
- **Final completion:** 2018-11-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03183024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03183024, "Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03183024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*